Nektar Total Assets from 2010 to 2025

NKTR Stock

USD 1.10 0.14 14.58%

Nektar Therapeutics Total Assets yearly trend continues to be relatively stable with very little volatility. Total Assets are likely to grow to about 707.3 M this year. Total Assets is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. View All Fundamentals

Total Assets

First Reported

1994-03-31

Previous Quarter

343.3 M

Current Value

308 M

Quarterly Volatility

509 M

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Check Nektar Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Nektar Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 17.6 M, Interest Expense of 23.9 M or Total Revenue of 162.3 M, as well as many indicators such as Price To Sales Ratio of 1.3, Dividend Yield of 0.0 or PTB Ratio of 0.7. Nektar financial statements analysis is a perfect complement when working with Nektar Therapeutics Valuation or Volatility modules.

Check out the analysis of Nektar Therapeutics Correlation against competitors.

To learn how to invest in Nektar Stock, please use our How to Invest in Nektar Therapeutics guide.

Latest Nektar Therapeutics' Total Assets Growth Pattern

Below is the plot of the Total Assets of Nektar Therapeutics over the last few years. Total assets refers to the total amount of Nektar Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Nektar Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. It is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. Nektar Therapeutics' Total Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Nektar Therapeutics' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 398.03 M

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Total Assets

Timeline

Nektar Total Assets Regression Statistics

	Arithmetic Mean	789,664,161
	Geometric Mean	561,249,465
	Coefficient Of Variation	75.84
	Mean Deviation	453,103,420
	Median	568,871,000
	Standard Deviation	598,865,587
	Sample Variance	358640T
	Range	2.1B
	R-Value	0.30
	Mean Square Error	349881.8T
	R-Squared	0.09
	Significance	0.26
	Slope	37,622,536
	Total Sum of Squares	5379599.9T

Nektar Total Assets History

	2025	707.3 M
	2024	457.7 M
	2023	398 M
	2022	710.6 M
	2021	1.1 B
	2020	1.5 B
	2019	2 B

Other Fundumenentals of Nektar Therapeutics

Intangibles To Total Assets

Nektar Therapeutics Total Assets component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Total Liab	Total Current Assets	Short Term Debt	Current Deferred Revenue	Short Term Investments	Common Stock	Net Receivables	Long Term Debt	Property Plant Equipment	Good Will	Intangible Assets	Net Tangible Assets	Long Term Debt Total	Capital Surpluse	Deferred Long Term Liab	Long Term Investments	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.98	0.07	-0.05	0.59	0.5	0.99	0.49	-0.15	0.99	-0.34	0.92	0.18	-0.16	0.06	-0.6	0.94	0.43	0.49	-0.52	0.74	0.42	0.94	0.96	-0.11
Total Stockholder Equity	0.98		-0.06	0.02	0.57	0.31	0.97	0.45	-0.22	0.97	-0.18	0.91	0.28	-0.1	0.12	-0.53	0.98	0.38	0.53	-0.49	0.8	0.4	0.96	0.99	-0.09
Net Debt	0.07	-0.06		-0.03	-0.15	0.52	0.03	0.56	0.32	0.07	-0.38	-0.02	-0.27	-0.17	-0.09	-0.03	-0.1	0.09	-0.21	-0.02	-0.04	0.09	0.01	-0.15	-0.22
Retained Earnings	-0.05	0.02	-0.03		-0.49	-0.2	-0.11	0.15	0.66	-0.09	0.64	0.1	-0.1	-0.14	0.79	0.81	-0.06	-0.7	-0.72	0.74	0.47	-0.67	0.24	0.06	-0.74
Accounts Payable	0.59	0.57	-0.15	-0.49		0.31	0.65	0.31	-0.56	0.64	-0.33	0.49	0.24	-0.04	-0.26	-0.7	0.59	0.52	0.72	-0.64	0.04	0.5	0.42	0.57	0.36
Total Liab	0.5	0.31	0.52	-0.2	0.31		0.47	0.36	0.34	0.44	-0.81	0.46	-0.35	-0.32	-0.06	-0.44	0.19	0.4	0.01	-0.23	0.09	0.18	0.36	0.32	-0.25
Total Current Assets	0.99	0.97	0.03	-0.11	0.65	0.47		0.43	-0.23	0.99	-0.33	0.92	0.27	-0.14	0.03	-0.63	0.94	0.51	0.56	-0.59	0.68	0.49	0.92	0.96	-0.04
Short Term Debt	0.49	0.45	0.56	0.15	0.31	0.36	0.43		0.08	0.47	-0.19	0.3	-0.37	-0.12	0.08	-0.19	0.41	-0.18	0.03	0.05	0.4	-0.08	0.46	0.36	-0.22
Current Deferred Revenue	-0.15	-0.22	0.32	0.66	-0.56	0.34	-0.23	0.08		-0.25	-0.03	-0.04	-0.5	-0.47	0.51	0.6	-0.36	-0.44	-0.83	0.66	0.19	-0.63	0.03	-0.17	-0.8
Short Term Investments	0.99	0.97	0.07	-0.09	0.64	0.44	0.99	0.47	-0.25		-0.28	0.9	0.3	-0.08	0.04	-0.61	0.95	0.48	0.56	-0.58	0.69	0.48	0.93	0.95	-0.04
Common Stock	-0.34	-0.18	-0.38	0.64	-0.33	-0.81	-0.33	-0.19	-0.03	-0.28		-0.21	0.39	0.28	0.5	0.72	-0.12	-0.57	-0.3	0.46	0.11	-0.38	-0.1	-0.15	-0.17
Net Receivables	0.92	0.91	-0.02	0.1	0.49	0.46	0.92	0.3	-0.04	0.9	-0.21		0.33	-0.13	0.24	-0.4	0.84	0.44	0.37	-0.41	0.7	0.42	0.91	0.93	-0.24
Long Term Debt	0.18	0.28	-0.27	-0.1	0.24	-0.35	0.27	-0.37	-0.5	0.3	0.39	0.33		0.17	0.07	-0.07	0.35	0.52	0.47	-0.53	0.11	0.61	0.24	0.31	0.19
Property Plant Equipment	-0.16	-0.1	-0.17	-0.14	-0.04	-0.32	-0.14	-0.12	-0.47	-0.08	0.28	-0.13	0.17		0.09	0.01	-0.07	-0.11	0.2	0.02	-0.25	-0.02	-0.19	-0.08	0.3
Good Will	0.06	0.12	-0.09	0.79	-0.26	-0.06	0.03	0.08	0.51	0.04	0.5	0.24	0.07	0.09		0.66	-0.04	-0.46	-0.52	0.53	0.31	-0.5	0.3	0.2	-0.77
Intangible Assets	-0.6	-0.53	-0.03	0.81	-0.7	-0.44	-0.63	-0.19	0.6	-0.61	0.72	-0.4	-0.07	0.01	0.66		-0.58	-0.73	-0.83	0.83	-0.07	-0.71	-0.33	-0.48	-0.58
Net Tangible Assets	0.94	0.98	-0.1	-0.06	0.59	0.19	0.94	0.41	-0.36	0.95	-0.12	0.84	0.35	-0.07	-0.04	-0.58		0.39	0.61	-0.56	0.77	0.47	0.9	0.95	0.07
Long Term Debt Total	0.43	0.38	0.09	-0.7	0.52	0.4	0.51	-0.18	-0.44	0.48	-0.57	0.44	0.52	-0.11	-0.46	-0.73	0.39		0.74	-0.89	-0.03	0.91	0.26	0.37	0.42
Capital Surpluse	0.49	0.53	-0.21	-0.72	0.72	0.01	0.56	0.03	-0.83	0.56	-0.3	0.37	0.47	0.2	-0.52	-0.83	0.61	0.74		-0.86	0.08	0.8	0.31	0.49	0.71
Deferred Long Term Liab	-0.52	-0.49	-0.02	0.74	-0.64	-0.23	-0.59	0.05	0.66	-0.58	0.46	-0.41	-0.53	0.02	0.53	0.83	-0.56	-0.89	-0.86		-0.05	-0.91	-0.32	-0.46	-0.55
Long Term Investments	0.74	0.8	-0.04	0.47	0.04	0.09	0.68	0.4	0.19	0.69	0.11	0.7	0.11	-0.25	0.31	-0.07	0.77	-0.03	0.08	-0.05		0.03	0.87	0.79	-0.38
Short Long Term Debt	0.42	0.4	0.09	-0.67	0.5	0.18	0.49	-0.08	-0.63	0.48	-0.38	0.42	0.61	-0.02	-0.5	-0.71	0.47	0.91	0.8	-0.91	0.03		0.24	0.36	0.55
Net Invested Capital	0.94	0.96	0.01	0.24	0.42	0.36	0.92	0.46	0.03	0.93	-0.1	0.91	0.24	-0.19	0.3	-0.33	0.9	0.26	0.31	-0.32	0.87	0.24		0.96	-0.32
Net Working Capital	0.96	0.99	-0.15	0.06	0.57	0.32	0.96	0.36	-0.17	0.95	-0.15	0.93	0.31	-0.08	0.2	-0.48	0.95	0.37	0.49	-0.46	0.79	0.36	0.96		-0.14
Capital Stock	-0.11	-0.09	-0.22	-0.74	0.36	-0.25	-0.04	-0.22	-0.8	-0.04	-0.17	-0.24	0.19	0.3	-0.77	-0.58	0.07	0.42	0.71	-0.55	-0.38	0.55	-0.32	-0.14

Click cells to compare fundamentals

About Nektar Therapeutics Financial Statements

Nektar Therapeutics shareholders use historical fundamental indicators, such as Total Assets, to determine how well the company is positioned to perform in the future. Although Nektar Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Nektar Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Nektar Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.

	Last Reported	Projected for Next Year
Total Assets	457.7 M	707.3 M
Intangibles To Total Assets	0.12	0.15

Pair Trading with Nektar Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Nektar Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Nektar Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Nektar Stock

0.87	DNLI	Denali Therapeutics	Pair Corr
0.63	EVOK	Evoke Pharma	Pair Corr
0.82	FOLD	Amicus Therapeutics	Pair Corr
0.87	JNJ	Johnson Johnson Fiscal Year End 28th of January 2025	Pair Corr

Moving against Nektar Stock

0.77	LFCR	Lifecore Biomedical	Pair Corr
0.66	BMY	Bristol Myers Squibb	Pair Corr
0.48	GILD	Gilead Sciences	Pair Corr
0.4	IMCC	Im Cannabis Corp	Pair Corr

The ability to find closely correlated positions to Nektar Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Nektar Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Nektar Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Nektar Therapeutics to buy it.

The correlation of Nektar Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Nektar Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Nektar Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Nektar Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for Nektar Stock Analysis

When running Nektar Therapeutics' price analysis, check to measure Nektar Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nektar Therapeutics is operating at the current time. Most of Nektar Therapeutics' value examination focuses on studying past and present price action to predict the probability of Nektar Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nektar Therapeutics' price. Additionally, you may evaluate how the addition of Nektar Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC